SC 13G | 2021-05-26 | Point72 Asset Management, L.P. | Aerpio Pharmaceuticals, Inc. | 1,825,000 | 3.9% | EDGAR |
SC 13G/A | 2021-02-10 | BML Investment Partners, L.P. | Aerpio Pharmaceuticals, Inc. | 2,008,942 | 4.3% | EDGAR |
SC 13G | 2021-02-10 | VANGUARD GROUP INC | Aerpio Pharmaceuticals, Inc. | 2,711,579 | 5.8% | EDGAR |
SC 13G | 2021-01-11 | Ikarian Capital, LLC | Aerpio Pharmaceuticals, Inc. | 475,778 | 1.0% | EDGAR |
SC 13D/A | 2020-11-23 | Satter Muneer A | Aerpio Pharmaceuticals, Inc. | 5,621,835 | 11.9% | EDGAR |
SC 13D/A | 2020-11-12 | ORBIMED ADVISORS LLC | Aerpio Pharmaceuticals, Inc. | 5,193,946 | 11.0% | EDGAR |
SC 13D/A | 2020-05-15 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 635,236 | 1.6% | EDGAR |
SC 13D/A | 2020-04-22 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 3,147,667 | 7.8% | EDGAR |
SC 13G | 2020-03-09 | BML Investment Partners, L.P. | Aerpio Pharmaceuticals, Inc. | 2,140,231 | 5.3% | EDGAR |
SC 13D/A | 2019-06-07 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 3,585,840 | 8.8% | EDGAR |
SC 13D/A | 2019-04-29 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 4,049,804 | 10.0% | EDGAR |
SC 13D/A | 2019-04-11 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 4,919,801 | 12.1% | EDGAR |
SC 13D/A | 2019-03-28 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 5,482,904 | 13.5% | EDGAR |
SC 13D/A | 2019-01-11 | Satter Muneer A | Aerpio Pharmaceuticals, Inc. | 5,621,835 | 13.9% | EDGAR |
SC 13D/A | 2018-10-04 | Kearny Venture Partners LP | Aerpio Pharmaceuticals, Inc. | 270,907 | 0.0% | EDGAR |
SC 13D/A | 2018-07-09 | Novartis Bioventures Ltd | Aerpio Pharmaceuticals, Inc. | 5,805,550 | 15.0% | EDGAR |
SC 13D/A | 2018-07-03 | Satter Muneer A | Aerpio Pharmaceuticals, Inc. | 5,078,017 | 13.1% | EDGAR |
SC 13D/A | 2018-07-02 | ORBIMED ADVISORS LLC | Aerpio Pharmaceuticals, Inc. | 5,193,946 | 13.4% | EDGAR |
SC 13D | 2017-03-28 | Kearny Venture Partners LP | Aerpio Pharmaceuticals, Inc. | 1,571,475 | 5.8% | EDGAR |
SC 13D | 2017-03-27 | ORBIMED ADVISORS LLC | Aerpio Pharmaceuticals, Inc. | 4,416,446 | 16.3% | EDGAR |